Towards the end of December, without conducting any outreach to industry groups or consumer organizations, the Federal Trade Commission issued a new guidance document, Health Products Compliance Guidance. The new guidance is remarkable for many reasons, particularly for its frequently aggressive stances that outstrip established law in the field. For instance, the FTC now purports to require randomized, controlled, human clinical trials as the default substantiation for any health-related claim.
Learn more about the guidance and its implications for companies making health-related advertising claims in Lathrop GPM’s client alert.